A double-blind, randomized, placebo-controlled phase III trial demonstrated the safety and efficacy of oral molnupiravir in unvaccinated and non-hospitalized adults. In addition, molnupiravir reduced the risk of clinical progression of COVID-19, thereby reducing the risk of hospitalization or death. Researchers across the globe are persistently striving to develop new preventive and therapeutic strategies to fight against COVID-19.
On the backdrop of emerging variants and a hike in cases, the need for promising strategies is even more pressing. Recently a phase III clinical trial demonstrated the safety and efficacy of oral molnupiravir in treating mild to moderate COVID-19 symptoms in adults. Study design: Potential benefits of molnupiravir: Patient-friendly feature Reduction in community transmission rate Reduction in COVID-19 related hospitalization Thus, molnupiravir’s efficacy in…
